Skip to Content
U.S. National Institutes of Health
Last Updated: 06/25/14

Selected RRP Staff Publications

  1. Radiation-induced brain damage, impact of Robbins’ work and the need for predictive biomarkers.
    Prasanna PG, Ahmed MM, Stone HB, Vikram B, Mehta MP, Coleman CN. Int J Radiat Biol. 2014 May 21:1-50. [Epub ahead of print] PMID: 24844376.

  2. Mitigating the risk of radiation-induced cancers: limitations and paradigms in drug development.
    Yoo SS, Jorgensen TJ, Kennedy AR, Boice Jr JD, Shapiro A, Hu TC, Moyer BR, Grace MB, Kelloff GJ, Fenech M, Prasanna PG, Coleman CN. J Radiol Prot. 2014 Apr 14;34(2):R25-R52. [Epub ahead of print] PMID:24727460 [PubMed — as supplied by publisher]

  3. Brachytherapy boost in loco-regionally advanced nasopharyngeal carcinoma: a prospective randomized trial of the International Atomic Energy Agency.
    Rosenblatt E, Abdel-Wahab M, El-Gantiry M, Elattar I, Bourque JM, Afiane MH, Benjaafar N, Abubaker S, Chansilpa Y, Vikram B, Levendag P. Radiat Oncol. 2014 Mar 1; 9(1):67. PMID: 24581393

  4. Premature chromosome condensation in human resting peripheral blood lymphocytes without mitogen stimulation for chromosome aberration analysis using specific whole chromosome DNA hybridization probes.
    Pathak R, Prasanna PG. Methods Mol Biol. 2014; 1105:171-81. PMID:24623228

  5. Assessment of biodosimetry methods for a mass-casualty radiological incident: medical response and management considerations.
    Sullivan JM, Prasanna PG, Grace MB, Wathen LK, Wallace RL, Koerner JF, Coleman CN.
    Health Phys. 2013 Dec;105(6):540-54. PMID:24162058

  6. mRNA Expression Profiles for Prostate Cancer following Fractionated Irradiation Are Influenced by p53 Status.
    Simone CB 2nd, John-Aryankalayil M, Palayoor ST, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN. Transl Oncol. 2013 Oct 1;6(5):573-85. eCollection 2013.PMID:24151538

  7. Nanotechnology in Radiation Research.
    Rao V.L. Papineni, Pataje G.S. Prasanna, Mansoor M. Ahmed (2013). Society forTranslational Cancer Research (Vol. 2). (K. Ji, Ed.) Sheung Wan, Hong Kong: Pioneer Bioscience Publishing Company.

  8. G-CSF rescues tumor growth and neo-angiogenesis during liver metastasis under host angiopoietin-2 deficiency.
    Im JH, Tapmeier T, Balathasan L, Gal A, Yameen S, Hill S, Smart S, Noterdaeme O, Kelly M, Brady M, Fu W, Kruse K, Bernhard EJ, Augustin HG, Muschel RJ. Int J Cancer. 2013 Jan 15;132(2):315-26. Epub 2012 Jul 3. PMID:22699974

  9. NCI support for particle therapy: past, present, future.
    Deye JA.
    Health Phys. 2012 Nov;103(5):662-6. PMID: 23032896

  10. Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance.
    Bekelman JE, Deye JA, Vikram B, Bentzen SM, Bruner D, Curran WJ Jr, Dignam J, Efstathiou JA, FitzGerald TJ, Hurkmans C, Ibbott GS, Lee JJ, Merchant TE, Michalski J, Palta JR, Simon R, Ten Haken RK, Timmerman R, Tunis S, Coleman CN, Purdy J.
    Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):782-90. Epub 2012 Mar 15. PMID: 22425219

  11. PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG.
    Kramer-Marek G, Bernardo M, Kiesewetter DO, Bagci U, Kuban M, Aras O, Zielinski R, Seidel J, Choyke P, Capala J. J Nucl Med. 2012 Jun;53(6):939-46. Epub 2012 May 11. Erratum in: J Nucl Med. 2012 Jul;53(7):1169. PMID:22582046

  12. Normal tissue protection for improving radiotherapy: Where are the Gaps?
    Prasanna PG, Stone HB, Wong RS, Capala J, Bernhard EJ, Vikram B, Coleman CN.
    Transl Cancer Res. 2012 Jun;1(1):35-48.PMID: 22866245

  13. Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model.
    Kramer-Marek G, Gijsen M, Kiesewetter DO, Bennett R, Roxanis I, Zielinski R, Kong A, Capala J. J Nucl Med. 2012 Apr;53(4):629-37. Epub 2012 Mar 12.PMID: 22410461

  14. A realistic utilization of nanotechnology in molecular imaging and targeted radiotherapy of solid tumors.
    Patel V, Papineni RV, Gupta S, Stoyanova R, Ahmed MM.
    Radiat Res. 2012 Apr;177(4):483-95. Epub 2012 Mar 9. Review. PMID:22404738

  15. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET.
    Kramer-Marek G, Shenoy N, Seidel J, Griffiths GL, Choyke P, Capala J.
    Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):1967-76. Epub 2011 Apr 20. PMID: 21748382

  16. Biological Dosimetry by the Triage Dicentric Chromosome Assay - Further validation of International Networking.
    Wilkins RC, Romm H, Oestreicher U, Marro L, Yoshida MA, Suto Y, Prasanna PG.
    Radiat Meas. 2011 Sep 1;46(9):923-928. PMID:21949482

  17. New Translational Possibilities for Microenvironmental Modulation of Radiosensitivity.
    Glazer PM, Le QT, Bristow R, Helleday T, Pelroy R, Bernhard EJ.Radiat Res. 2011 Jul 8. [Epub ahead of print] PMID: 21740252

  18. Addressing Cancer Disparities Among American Indians through Innovative Technologies and Patient Navigation: The Walking Forward Experience.
    Petereit DG, Guadagnolo BA, Wong R, Coleman CN. Front Oncol. 2011 Jun 22;1:11. eCollection 2011. PMID: 22649752

  19. Disaster preparation: lessons from Japan.
    Coleman CN, Simon SL, Noska MA, Telfer JL, Bowman T. Science. 2011 Jun 17;332(6036):1379. PMID:21680826

  20. Unaltered ethical standards for individual physicians in the face of drastically reduced resources resulting from an improvised nuclear device event.
    Caro JJ, Coleman CN, Knebel A, DeRenzo EG.
    J Clin Ethics. 2011 Spring;22(1):33-41. PMID: 21595353

  21. Preparing and planning for a catastrophic incident of a nuclear detonation. Foreword.
    Coleman CN, Knebel AR, Lurie N. Disaster Med Public Health Prep. 2011 Mar;5 Suppl 1:S11-2. PMID: 21402802

  22. Scarce resources for nuclear detonation: project overview and challenges.
    Coleman CN, Knebel AR, Hick JL, Weinstock DM, Casagrande R, Caro JJ, DeRenzo EG, Dodgen D, Norwood AE, Sherman SE, Cliffer KD, McNally R, Bader JL, Murrain-Hill P.
    Disaster Med Public Health Prep. 2011 Mar;5 Suppl 1:S13-9. PMID: 21402805

  23. Low-dose fractionated radiation potentiates the effects of cisplatin independent of the hyper-radiation sensitivity in human lung cancer cells.
    Gupta S, Koru-Sengul T, Arnold SM, Devi GR, Mohiuddin M, Ahmed MM.
    Mol Cancer Ther. 2011 Feb;10(2):292-302. Epub 2011 Jan 7. PMID:  21216938

  24. Biological Dosimetry by the Triage Dicentric Chromosome Assay: Potential Implications for Treatment of Acute Radiation Syndrome in Radiological Mass Casualties.
    Romm H, Wilkins RC, Coleman CN, Lillis-Hearne PK, Pellmar TC, Livingston GK, Awa AA, Jenkins MS, Yoshida MA, Oestreicher U, Prasanna PG. Radiat Res. 2011 Jan 4. [Epub ahead of print] PMID: 21204674

  25. Establishment of a Radiogenomics Consortium
    West C, Rosenstein BS, Alsner J, Azria D, Barnett G, Begg A, Bentzen S, Burnet N, Chang-Claude J, Chuang E, Coles C, De Ruyck K, De Ruysscher D, Dunning A, Elliott R, Fachal L, Hall J, Haustermans K, Herskind C, Hoelscher T, Imai T, Iwakawa M, Jones D, Kulich C; EQUAL-ESTRO, Langendijk JH, O’Neils P, Ozsahin M, Parliament M, Polanski A, Rosenstein B, Seminara D, Symonds P, Talbot C, Thierens H, Vega A, West C, Yarnold J. Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1295-6. PMID: 20338472

    This report describes the formation of a Radiogenomics Consortium established to aid in the identification of genetic variants, primarily single nucleotide polymorphisms (SNPs), associated with the development of normal tissue toxicities resulting from radiation therapy.

  26. A Small Interfering RNA Screen of Genes Involved in DNA Repair Identifies Tumor-Specific Radiosensitization by POLQ Knockdown
    Higgins GS, Prevo R, Lee YF, Helleday T, Muschel RJ, Taylor S, Yoshimura M, Hickson ID, Bernhard EJ, McKenna WG. Cancer Res. 2010 Mar 16. [Epub ahead of print]PMID: 20233878

    This publication describes a novel method for high throughput screening for synthetic lethality of molecular targeting combined with radiation. The DNA repair enzyme Pol Q is newly identified as a contributor to tumor cell survival after irradiation.

  27. Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy
    Maity A, Bernhard EJ. Cancer Res. 2010 Mar 15;70(6):2141-5. Epub 2010 Feb 23.PMID: 20179191

    This review describes new findings that inhibition of tumor cell signaling can enhance tumor response to radiation and cytotoxic drugs by enhancing vascular function and tumor oxygenation.

  28. Triage dose assessment for partial-body exposure: dicentric analysis
    Prasanna PG, Moroni M, Pellmar TC. Health Phys. 2010 Feb;98(2):244-51.PMID: 20065689

  29. Distinct signaling pathways after higher or lower doses of radiation in three closely related human lymphoblast cell lines
    Lu TP, Lai LC, Lin BI, Chen LH, Hsiao TH, Liber HL, Cook JA, Mitchell JB, Tsai MH, Chuang EY. Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):212-9.PMID: 20005454

  30. Improving cancer outcomes through international collaboration in academic cancer treatment trials.
    Trimble EL, Abrams JS, Meyer RM, Calvo F, Cazap E, Deye J, Eisenhauer E, Fitzgerald TJ, Lacombe D, Parmar M, Seibel N, Shankar L, Swart AM, Therasse P, Vikram B, von Frenckell R, Friedlander M, Fujiwara K, Kaplan RS, Meunier F. J Clin Oncol. 2009 Oct 20;27(30):5109-14. Review.PMID: 19720905

  31. Current status and future potential of advanced technologies in radiation oncology. Part 2. State of the science by anatomic site
    Vikram B, Coleman CN, Deye JA. Oncology (Williston Park). 2009 Apr 15;23(4):380-5.PMID: 19476269

  32. Current status and future potential of advanced technologies in radiation oncology. Part 1. Challenges and resources
    Vikram B, Coleman CN, Deye JA. Oncology (Williston Park). 2009 Mar;23(3):279-83. Review. PMID: 19418829

  33. Re: Intensity-modulated radiation therapy dose prescription, recording, and delivery: patterns of variability among institutions and treatment planning systems
    Deye J, Purdy J, Vikram B. J Natl Cancer Inst. 2008 Sep 3;100(17):1263-4; author reply 1265-7. Epub 2008 Aug 26. PMID: 18728288

  34. Radiation event medical management (REMM): website guidance for health care providers
    Bader JL, Nemhauser J, Chang F, Mashayekhi B, Sczcur M, Knebel A, Hrdina C, Coleman CN. Prehosp Emerg Care. 2008 Jan-Mar;12(1):1-11.PMID: 18189170